What's in Steno Diabetes Center Copenhagen's pipeline?

Steno Diabetes Center Copenhagen has 9 drugs in our index: 6 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 2 in Phase 1.

Which companies overlap with Steno Diabetes Center Copenhagen's portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC, Sanofi, Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/steno-diabetes-center-copenhagen.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Steno Diabetes Center Copenhagen — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Steno Diabetes Center Copenhagen pipeline: 6 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 1 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
LOKELMA 5 GM Powder for Oral Suspension	LOKELMA 5 GM Powder for Oral Suspension	marketed	Potassium binder	Potassium ion (K+) in gastrointestinal tract	Nephrology / Cardiology
Placebo-Repaglinide	Placebo-Repaglinide	marketed	Meglitinide (rapid-acting insulin secretagogue)	ATP-sensitive potassium channel / Sulfonylurea receptor	Diabetes
Placebo-Metformin	Placebo-Metformin	marketed	Biguanide	AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase	Diabetes
insulin aspart + insulin aspart protamin	insulin aspart + insulin aspart protamin	marketed	Insulin (biphasic rapid-acting insulin analog)	Insulin receptor	Diabetes
Low-Dose Glucagon	Low-Dose Glucagon	marketed	Glucagon receptor agonist	Glucagon receptor (GCGR)	Diabetes
Spironolacton (hexalacton(R))	Spironolacton (hexalacton(R))	marketed	Potassium-sparing diuretic; aldosterone antagonist	Mineralocorticoid receptor (MR)	Cardiovascular
Irbesartan treatment	Irbesartan treatment	phase 3	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)	Cardiovascular

Therapeutic area mix

Diabetes · 4
Cardiovascular · 2
Nephrology / Cardiology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 3 shared drug classes
Sanofi · 2 shared drug classes
Bristol-Myers Squibb · 2 shared drug classes
Eli Lilly and Company · 2 shared drug classes
AstraZeneca · 2 shared drug classes
Boryung Pharmaceutical Co., Ltd · 1 shared drug class
Bayer · 1 shared drug class
Arbor Pharmaceuticals, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Steno Diabetes Center Copenhagen:

Cite this brief

Drug Landscape (2026). Steno Diabetes Center Copenhagen — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/steno-diabetes-center-copenhagen. Accessed 2026-05-18.